<?xml version="1.0" encoding="UTF-8"?>
<p id="p0035">Evaluating the baseline infection risk of patients isÂ an important aspect of risk stratification. Several immune-mediated conditions, such as psoriasis and lupus, are associated with increased infection risk irrespective of exposure to immunomodulatory agents.
 <xref rid="bib1" ref-type="bibr">
  <sup>1</sup>
 </xref>
 <sup>,</sup>
 <xref rid="bib2" ref-type="bibr">
  <sup>2</sup>
 </xref> Many of these conditions are further associated with comorbidities known to predict poor outcomes in COVID-19 infection (eg, diabetes and obesity in patients with psoriasis, asthma in patients with atopic dermatitis, and interstitial lung disease with connective tissue disorders).
 <xref rid="bib3" ref-type="bibr">
  <sup>3</sup>
 </xref> Each patient presents a unique set of variables that dictate the approach to their therapy plan. A summary of these considerations is found in 
 <xref rid="tbl1" ref-type="table">Table I</xref> .
</p>
